Background and rationale
Increasing the capacity of the immune system to mediate tumor regression has been a major goal for tumor immunologists. Progress towards tumor vaccines has been recently made by the molecular identification of novel tumor-associated antigens (TAA) and by a better understanding of cellular signals required for efficient T cell activation. 1 Unlike vaccines for infectious diseases, cancer vaccination is of therapeutic rather than prophylactic nature, involving attempts to activate immune responses against TAA to which the immune system has already been exposed. However, the occurrence of lethal human tumors implies the failure of the immune system to recognize TAA and to subsequently eradicate the tumor, which is in contrast to the seminal hypothesis of Burnet, 2 who put forward the concept of an 'immune surveillance' concept, in which the immune system would eradicate newly arisen tumor cells. A number of mechanisms have been proposed to explain the futility, or even absence, of immunological intervention in tumor-bearing hosts. Loss of major histocompatibility complex (MHC) class I molecules, absence of costimulatory molecules, emergence of antigen-loss tumor variants, impaired antigen processing machinery, or production of immunosuppressive or -modulating factors, such as trans- forming growth factor (TGF)-␤, 3 vascular endothelial growth factor (VEGF), 4 interleukin (IL)-10, 5 or expression of deathinducing molecules like Fas ligand, 6 are examples of immune escape routes that are likely to play a role in many types of cancers ( Figure 1 ). All these mechanisms have been shown to induce T cell tolerance because of ignorance, anergy, physical deletion, or active immunosuppression, and have been discussed at length. 7, 8 To date, advances in gene delivery technology have led to the development of immuno-gene therapy strategies to augment host-immune responses to tumors. 9, 10 These approaches include (1) the use of tumor cells genetically modified with genes encoding costimulatory ligands, cytokines or HLA molecules to enhance their immunogenicity and (2) the genetic modification of immune-competent cells with TAA in order to enhance their anti-tumor response (Table 1) . 11, 12 The main rationale of genetic immunopotentiation protocols is the possibility of enlisting the immune system for a potentially vast amplification of gene therapy, thereby enhancing therapeutic benefit. 13 
Gene-modified cytotoxic T cells
Tumor-infiltrating lymphocytes (TIL) are derived from mononuclear cells isolated from resected specimens of solid tumors. In the 1990s, it was hypothesized that TIL could represent an enriched source of CTL and natural killer (NK) cells, specific for the tumor, and that they could home in the tumor sites. 14 As TIL could be readily manipulated ex vivo, they were the first immune cells to be genetically modified and applied in a human gene therapy trial. 15 This trial involved retroviral marking with a neomycine resistance (neo R ) gene of TIL in patients with advanced melanoma. Gene marking allowed assessment of the long-term cell distribution and survival of reinfused TIL. The results indicated that (1) small numbers of transduced TIL persisted in the circulation for at least 3 weeks; (2) transduced TIL were recovered from tumor deposits in three of five patients, from 6 days to 2 months after administration to the patient; and (3) most importantly, no detrimental effects were observed following retroviral transduction, establishing the potential safety of gene therapy for cancer. Therefore, it was hypothesized that transfer of immunity-enhancing cytokine genes, such as tumor necrosis factor (TNF)-␣, to TIL could deliver therapeutic local cytokine concentrations to tumor deposits, thereby avoiding the toxicity related to systemically administered cytokines. 16, 17 However, it was also observed that, although TIL included activated CTL and NK cells, only few of these cells were tumor-specific. Furthermore, the potential of reinfused TIL to relocate to the tumor site was very low and the efficacy of TIL reinfusion was likely to be linked to co-administration of high-dose IL-2, which also has toxic side-effects. 18 In order to overcome TIL dependency
Figure 1
Immune tolerance to tumors. T cell tolerance is emerging as one of the leading mechanisms by which tumors evade immune recognition. Tumor cells can directly interact with T cells and promote tumor escape through (1) defective antigen presentation leading to T cell ignorance; (2) induction of T cell anergy through lack of expression of costimulatory molecules (eg B7 family) on the tumor cell; (3) or active immunosuppression via secretion of immunosuppressive factors, depletion of tumor-specific T cells (through Fas-FasL interaction) or via induction of suppressor T cells. Tumor cells can also indirectly evade T cell recognition by impairing local DC function and blocking DC development from hematopoietic progenitors, through local secretion of IL-10 and VEGF. TAA, tumor-associated antigens; MHC, major histocompatibility complex; TAP, transporter associated with antigen processing; TGF, transforming growth factor; IL, interleukin; DC, dendritic cells; VEGF, vascular endothelial growth factor; FasL, Fas ligand. on IL-2, which is otherwise necessary for their in vivo proliferation and persistence, TIL were genetically modified with chimeric receptors containing the extracellular domains of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor and the transmembrane and cytoplasmic domain of the IL-2 receptor. 19 Thus, the production of GM-CSF by such modified CD8
+ CTL, which normally occurs upon antigen recognition, could potentially provide an endogenous IL-2 receptor signal to the CTL and improve in vivo survival and proliferation. Moreover, these chimeric receptors could provide a means to establish the fate and distribution of reinfused genetically modified T cells.
Genetically re-engineering the tumor tropism was recently demonstrated using chimeric receptors composed of single chain immunoglobulin fragments (scFv) serving as extracellular recognition elements joined to lymphocyte triggering molecules, eg the Fc␥ receptor (the so-called 'T bodies'). 20, 21 Upon encountering their target cells bearing an membranebound tumor marker, eg carcino-embryonic antigen (CEA), 22 T bodies are able to undergo MHC-independent stimulation for interleukin/cytokine production, and kill tumor cells in in vitro and in vivo model systems. It is anticipated that genetically modified TIL with such enhanced functions will be clinically evaluated in the future and may provide recipients with more effective responses than those achieved with unmodified TIL therapy.
The co-incorporation of a herpes simplex virus thymidine kinase (HSV-TK) 'suicide' gene into the vector, conferring sensitivity to ganciclovir, is being used as a safety measure in T cell-based gene marking or gene therapy protocols allowing elimination of transduced cells if undesirable side-effects develop. 23 In the context of allogeneic bone marrow transplantation (allo-BMT), suicide gene-based strategies have been explored to promote a graft-versus-leukemia effect while minimizing graft-versus-host disease (GVHD) and have already entered the clinical phase. 24, 25 Recently, Bordignon and co-workers 24 treated eight patients, who relapsed or developed Epstein-Barr virus-induced lymphoma after T celldepleted allo-BMT, with donor lymphocytes transduced with HSV-TK suicide gene. HSV-TK + donor lymphocytes survived for up to 12 months after infusion, resulting in antitumor activity in five patients. Three patients developed GVHD, which could be effectively controlled by ganciclovir-induced elimination of the transduced cells. 26 Despite the positive results of the pilot clinical trial, the induction of a strong immune response against the neo R gene encoded by the retroviral vectors was observed in two patients. Therefore, new generation retroviral vectors lacking the neo R gene but carrying a modified form of the low-affinity nerve growth factor receptor (⌬LNGFR) cDNA as a selectable cell surface marker were developed. 27 These vectors were shown to be less immunogenic and able to confer higher ganciclovir sensitivity to transduced human lymphocytes. Furthermore, the expression of the ⌬LNGFR marker allows a faster immune selection of transduced cells compared with neo R selection. 
Gene-modified tumor cells
The recognition that most tumors encode TAA and are capable of inducing protective immunity in preclinical models has reinvigorated the field of cancer immunotherapy. 29 It has been hypothesized that the immune system of tumor patients, characterized by tolerance, can be modified to mount an immunological response against the tumor and thus facilitate tumor rejection. This 'cancer vaccination' is to be accomplished through exposure of TAA in a more favorable context to the immune system. 10 Despite ongoing efforts to define and characterize TAA and, more importantly, clinically relevant TAA, 30 little is known about TAA for the majority of human cancers and the largest part of clinical experience with tumor vaccines has been obtained in melanoma patients. 31, 32 Therefore, most cancer vaccines, to date, use tumor cells as a source of TAA.
For many years, tumor cells were mixed with adjuvants, such as Bacillus Calmette-Guérin (BCG) and Corynebacterium parvum, in an attempt to amplify tumor-specific immune responses. However, standardization of this approach was not possible due to batch variability and inconsistency of the tumor cell-adjuvant mixture. 33, 34 An alternative strategy, that may replace these complex mixtures of tumor cells and bacteria, is the use of gene-modified tumor cells in order to facilitate the start of an immune response. More than 10 years ago, the first papers describing genetic modification of tumor cells with IL-2 and IL-4 were published. 35, 36 The original working hypothesis of this approach was to provide cytokines to the CTL precursors as a means to circumvent CD4 + T helper dependence. 37, 38 The current rationale lies in the local recruitment of inflammatory cells that can destroy a fraction of the tumor cells directly or indirectly, thereby releasing tumor antigens. These antigens can be taken up in the form of peptides, proteins or apoptotic bodies by professional antigenpresenting cells (APC) by a process known as cross-priming (ie indirect presentation of tumor antigens to the immune system by a host-derived APC), 39 that travel to the draining lymph nodes where they will activate naive antigen-specific T cells and initiate a primary cellular immune response.
Initially, tumor cells were transduced with specific viral genes in order to enhance their immunogenicity. 40 In a later stage, transduction of tumor cells with genes encoding allogeneic HLA molecules was explored as a means to use nonself immunity against cancer. 41, 42 Allogeneic HLA genes (HLA-B7) have been chosen by Nabel and co-workers 43 for direct gene transfer into melanoma lesions in vivo using lipoplexes. They appear to augment specific immune responses in patients receiving this gene therapy, and one patient experienced complete tumor remission. In these studies, no toxicity or anti-DNA antibodies were demonstrated. 44 Currently, the most frequently studied gene-modified tumor vaccines take advantage of the large set of genes encoding cytokines 45 or costimulatory molecules, like B7-1 (CD80) and B7-2 (CD86), 46 in order to enhance the immunogenicity of the tumor. In a murine acute myeloid leukemia (AML) model, irradiated CD80-positive AML cells provided long-lasting (5 to 6 months) systemic immunity against subsequent challenge with wild-type AML cells and one exposure to irradiated CD80 + AML cells results in rejection of leukemia by leukemic mice when the vaccination occurs in the early stages of the disease. 47 Using the same model, Dunussi-Joannopoulos et al 48, 49 showed superiority of a GM-CSF-based vaccine to CD80, CD86, IL-4 or TNF-␣ gene-transduced AML cells in terms of eliciting leukemia-specific protective and therapeutic immunity. The therapeutic effects obtained with GM-CSF in preclinical 50 and recently in clinical 51, 52 studies might relate to its role in promoting local dendritic cell (DC) differentiation from hematopoietic precursors at the site of vaccination. 53 Because DC are known to be the primary cells necessary for activation of naive T cells, their role in priming immunological responses is now considered to be crucial (this is described in more detail below). Since comparative analysis between different cytokines has only been established at the preclinical level showing somewhat divergent results depending on the tumor model studied, 50, 54, 55 the search for the 'best' cytokine remains largely unsolved at the clinical level. Interestingly, a phase I trial demonstrated enhanced immunogenicity of GM-CSF gene-transduced over non-transduced renal carcinoma vaccines. 56 From recent observations in a murine adenocarcinoma 57, 58 and AML 59 model, IL-12 is also a promising cytokine with distinct therapeutic activity possibly due to its role in activation of the innate immune system and in the induction of a T helper type 1 (Th1)-mediated cellular response. Recently, these preclinical results have led to a phase I clinical study. 60 The technical difficulties involved in manipulation and transduction of autologous tumor cells have led to the development of alternative cytokine-based vaccine approaches. One approach is based on the observation that boosting the immune system does not need to be generated by cytokine production from the tumor itself, but can also be brought about by mixing tumor cells with cytokine gene-transduced bystander cells, eg with autologous 61 or allogeneic 62 fibroblasts or with HLA-negative cells. 63 This approach obviates the need for culture and transduction of each patient's tumor cells, a delicate procedure that is likely to be inefficient or practically impossible for some primary tumor cells. 64 Another approach currently under clinical investigation makes use of MHC-mismatched cytokine gene-transduced cell lines, based on the assumption that some TAA are shared between similar tumoral samples rather than being unique for a single patient's tumor. 65, 66 This strategy is often referred to as allogeneic tumor vaccines since the vaccinating cell line expresses a MHC profile, which is foreign to the vaccinated patient. It is now well understood that tumor antigens are presented by host bone marrow-derived APC rather than by the tumor, through cross-priming. 39 Therefore, MHC compatibility between patient and tumor is not a prerequisite in this type of vaccine. However, it remains unclear whether allogeneic gene-based vaccines, although logistically more simple, will prove therapeutically more efficient than their autologous counterparts. 67, 68 Lastly, the efficacy of vaccination with cytokine gene-modified tumor cells depends on the amount and rate of cytokine production released locally to promote recruitment and activation of inflammatory cells. Since growing tumor cells cannot be used in humans, irradiated or mitomycin-treated genemodified tumor cells are used for vaccine purposes. Such nonproliferating tumor cells, however, have been shown to be significantly less immunogenic than their replicating counter-parts in a murine adenocarcinoma model. 54 This could probably be explained by the reduced kinetics of cytokine release of nondividing cytokine gene-modified tumor cells. 64 Therefore, to fully assess the potential antitumor activity of genemodified tumor vaccines, further preclinical and clinical studies are needed.
Barriers to gene-based tumor vaccines

Gene transfer efficiency
Despite the continuous increase in clinical gene therapy protocols for immunotherapy of cancer, many aspects of gene transfer are still far from ideal. A basic requirement, not yet adequately and routinely fulfilled, is to introduce the gene of interest with sufficient efficiency into the target cells in order to achieve therapeutic benefit in cancer patients. The level of gene transfer into tumor cells and immune effector cells has been limited, and this has been thought to account, at least partly, for the poor results obtained by cancer gene immunotherapy. Therefore, vector design is one of the most critical areas for future research. As recombinant retroviruses are so far the best characterized viral vectors, they are most the frequently vectors used for immuno-gene therapy of cancer (reviewed by Roth and Cristiano 69 ). Advantages of retroviral gene transfer are relatively high ex vivo transduction efficiency and stable chromosomal integration leading to long-term transgene expression. However, for ex vivo gene delivery and clinical use in cancer protocols, retroviral vectors have numerous limitations including the limited DNA insert size (±10 kb), silencing of the long terminal repeat (LTR) promoter, and large-scale preparation. [70] [71] [72] Design of optimized transduction protocols and development of improved retroviral vectors, exhibiting improved transduction efficiency and stability for large-scale production, have just begun to be evaluated. [73] [74] [75] Nowadays, with the latest generation of packaging cell lines, the possibility of producing replication-competent retroviruses (RCR) has virtually been eliminated due to the lack of overlap between vector and helper constructs. 76, 77 The limitations of retroviral vectors have led to the development of alternative viral vectors for gene therapy. To this end, recombinant adenoviral vectors (AdV) have become an attractive alternative. 78, 79 AdV are capable of high-efficiency transduction of many cell types, regardless of the mitotic status of the cell. Furthermore, these vectors can be produced at substantially higher viral titers (Ͼ10 11 plaque-forming units/ml). 80 A major disadvantage in adenovirus-based gene therapy strategies, however, is the deleterious inflammatory responses against AdV characterized by humoral as well as cellular immune responses to viral components, thereby hampering prolonged transgene expression. 81 Moreover, the use of AdV for in vivo purposes in clinical trials is currently being questioned since administration of high-dose AdV vector to an 18-year-old patient enrolled in an ornithin transcarbamylase (OTC) gene therapy trial resulted in a fatal outcome due to a fulminant immune response. 82, 83 Notwithstanding this major obstacle, a controlled phase II trial involving the in vivo injection of replication-competent adenoviruses -ie adenoviruses with the E1B 55 kDa gene deleted and capable of selectively replicating in p53-deficient cancer cells -showed substantial objective responses, including a high portion of complete responses, in patients with recurrent head and neck cancer. 84 Also, AdV may hold promise for ex vivo immuno-gene therapy of cancer for which phase I trials are currently being conducted. 85 Alternative viral systems based on recombinant adeno-associated virus (AAV), 86, 87 poxviruses (including vaccinia and avipox virus) [88] [89] [90] have also received recent attention for ex vivo delivery of genes into tumor cells.
It should, however, be mentioned that the current wave of future viral vectors may be to use lentiviral vectors based on the human immunodeficiency virus type 1 (HIV-1). HIV-1-based vectors are able to transduce both dividing and nondividing cells and their cell tropism can be broadened by pseudotyping with the envelope G protein of the vesicular stomatitis virus (VSV-G). 91 As a result, these vectors can transduce virtually every cell type, including CD34 + CD38 − human hematopoietic stem cells. 92 In a recent report, Stripecke and colleagues 93 used lentiviral vectors to enhance the immunogenicity of primary acute leukemic cells, with superior efficiency. In order to improve the safety features of lentiviral vectors, self-inactivating (SIN) lentiviral vectors have been developed. 94, 95 In these vector constructs, the U3 region of the 5Ј long terminal repeat (LTR) was replaced with the cytomegalovirus (CMV) promoter, resulting in Tat-independent transcription but still maintaining high levels of expression. In addition, the U3 region of the 3Ј LTR contains a 133 bp deletion, including the TATA box and binding sites for transcription factors Sp1 and NF-kappaB. The deletion is transferred to the 5Ј LTR after reverse transcription and integration in infected cells, resulting in the transcriptional inactivation of the LTR in the proviruses. The inactivation design significantly improves the biosafety of HIV-derived vectors, as it reduces the likelihood that replication-competent lentiviruses will originate in the vector producer and target cells, and hampers recombination with wild-type HIV in an infected host. Therefore, these SIN vectors may provide a safer alternative for human gene therapy trials. 96 Finally, the potential of nonviral plasmid-based vector systems using liposomes or physical methods (gene gun, electroporation) for ex vivo gene delivery should not be overlooked as they circumvent the potential risks and drawbacks associated with viral vectors. Moreover, nonviral gene delivery systems are cost-and time-effective and large-scale manufacturing of clinical-grade plasmid vectors is logistically simple. 97 The major disadvantages are the low transfection efficiency and the transient expression in target cells. 98 As already mentioned earlier, one of the attractive features of immunological gene therapy approaches is that they capitalize on the ability to amplify the outcome of the gene transfer ('genetic immunopotentiation'). Consequently, highefficiency gene transfer may not be an essential requirement in these protocols. To date, several functional domains involved in viral entry, nuclear trafficking or viral protein expression are being introduced in nonviral vectors since trafficking, nuclear entry and maintenance of the transfected DNA in the cell are additional steps where nonviral systems may benefit from including viral elements.
99,100
Immune tolerance to tumors
Notwithstanding the limitations of current gene transfer technologies described above, there are other, probably more important, barriers that explain the modest clinical benefit of current tumor vaccine protocols. Van Pel and Boon 29 demonstrated that a protective immune response could be generated against a 'non-immunogenic' murine tumor, providing the first experimental evidence that the lack of tumor immunity was not due to the absence of TAA but rather to the inability to (Figure 1) . In fact, current knowledge of tumor immunology established that T cells, able to recognize TAA, could be found in vivo and in vitro. 10 Thus, this part of the lymphocyte repertoire has not been deleted, at least completely. Therefore, it is suggested that the futility, or even absence, of tumor immune response is due to (1) defective TAA presentation by the tumor leading to tumor escape and T cell ignorance; (2) induction of T cell anergy due to lack of costimulation; or (3) active tumor-induced immunosuppression (Figure 1) . Multiple tumor escape mechanisms, including TAA-loss variants, downregulation of MHC class I molecules, and a defective antigen-processing machinery, have been proposed to account for impaired antigen presentation of tumor cells. 7, 8, 101 Alternatively, it may well be that the lack of costimulatory molecules (eg CD80, CD86) on the surface of tumor cells accounts for the immune tolerance which keeps the tumor from being rejected. 102 In this regard, induction of anergy of tumor-specific T cells has been demonstrated in preclinical models to be an early event in the course of tumor progression. 103 In addition, the striking observation that tumors arising in cancer-prone transgenic mice could not be rejected by a cytokine-secreting tumor vaccine, whereas the same tumor vaccine was able to immunize non-transgenic mice grafted with similar tumors, questions the efficacy of tumor vaccines previously reported in animal models of grafted syngeneic tumors. 104 Similarly, a recent report demonstrated that in vivo transduction of solid nontransplanted tumors with genes encoding IL-7 and the costimulatory molecule B7.1 (CD80) does not lead to tumor rejection, while the same cancer vaccine efficiently induced rejection of transplanted tumors in a murine model. 105 Finally, deficiency of the immune system could be responsible for the lack of immunity and induction of T cell tolerance. In this case, the tumor actively suppresses host antigen presentation and immune effector functions by expression of a variety of local inhibitory molecules, such as VEGF and IL-10, especially when large tumor burdens are involved (Figure 1) . 106 This impediment favors an initial treatment plan to remove or kill most of the tumor cells in a non-immunological fashion, followed by immunotherapy to treat 'minimal residual disease', as well as to prevent relapse.
Together, immune tolerance to naturally induced tumors could impede successful vaccination against TAA and could abort most of the immunotherapeutic approaches discussed above. Therefore, in order to be effective, one could aim to activate a cryptic T cell population that escaped tolerance by virtue of low affinity for TAA expressed by the tumor. An alternative, and potentially more attractive, strategy would be to break down and reverse T cell tolerance. The latter strategy is discussed further below.
Overcoming barriers with new strategies
One can hypothesize that if gene transfer is going to be applied in a clinically relevant way, new ways to consider immunity against cancer are necessary. Instead of exploiting the increasing knowledge on cytokines and their plethora of actions in the immune response (for reviews, see Tuting et al 107 and Jantscheff et al 108 ) , one would rather emphasize a Leukemia novel working hypothesis in immunology that may provide a more fundamental mechanism to explain the immunological unresponsiveness to cancer than the classical self/non-self paradigm. At a later stage, we will focus on a new gene-based tumor vaccine strategy that seems to fit within this conceptual framework.
Danger and the breakdown of immune tolerance to tumors
According to the classical paradigm in tumor immunology, immune responses are believed to follow a model of discrimination between self and non-self. Consequently, tumors should be considered as non-self, like viruses or bacteria. Therefore, an important task of the immune system is to search for and destroy tumor cells as they arise, in concordance with the original proposals of Burnet's immunological surveillance hypothesis. 2 However, the limited successes of cancer immunotherapy approaches based on these concepts, prompted a revision of tumor immunology. Matzinger 109 proposed an alternative working hypothesis that may explain the observed failure of the immune system against tumors and offers exciting prospects for the development of novel strategies to combat cancer with one's own immune system. This model, termed the 'danger' model, capitalizes on the fact that the immune system has to maintain a delicate balance between avoiding lethal auto-immunity by induction of tolerance and defending against exogenous lethal pathogens by induction of a vigorous immune response. To maintain this well-balanced homeostasis, the default reaction when encountering an antigen is not necessarily immune activation. Indeed, numerous experiments demonstrate that contact of naive T cells with antigens often results in the induction of tolerance because of either ignorance, anergy or physical deletion through apoptosis. 110, 111 What determines the outcome of antigen recognition is the context in which the antigen is presented to the immune system. The default reaction to new (non-self) antigens presented by non-hematopoietic cells is tolerance, and it is the role of APC, in particular dendritic cells (DC), to sense 'danger', such as inflammation or cell damage due to viral or bacterial infection or when the antigen is mixed with an adjuvant, in order to induce a vigorous cellular immune response. 112 In the absence of 'danger', however, APC will process and present the antigen to T cells in a tolerogenic manner. In this view, it is hypothesized that the default reaction to TAA, that accumulate during malignant transformation in the absence of associated tissue distress or destruction, is tolerance as well. 113, 114 Ultimately, it appears that the immune response at the T cell level is based on the presence of the appropriate costimulatory molecules on APC that promote T cell activation. This has been described as the two-signal hypothesis.
115 Signal 1, provided by the T cell receptor recognizing the antigen, must be accompanied by a second signal, such as B7-CD28 interaction, in order to allow activation of naive T cells ( Figure 2) . But, as the APC themselves cannot distinguish between self from non-self, APC present antigens irrespective of their self or non-self origin. Therefore, immunologists have proposed the existence of a third signal, 116, 117 which danger theorists prefer to call 'danger' signals. 113 In absence of this third signal, APC will present captured antigens without costimulation and the typical outcome will be immunological tolerance. 118, 119 This model can change the emphasis which has been applied in immunotherapeutic approaches of cancer. In the
Figure 2
Necessary signals and cell interactions for optimal induction of a TAA-specific immune response. Immature DC are professional antigen-capturing cells that can be loaded with TAA using various strategies. In combination with a 'danger' signal, these TAA-loaded DC will undergo maturation with concomitant upregulation of surface markers involved in antigen presentation (eg MHC class II and B7 molecules). These mature DC are now ideal antigen-presenting cells able to stimulate naive CD4 + T cells. Ligation of the CD40 molecule by CD4 + helper T cell contact or by anti-CD40 antibodies will license DC to become effector DC that can now activate TAA-specific CTL precursors. TAA, tumor-associated antigens; MHC, major histocompatibility complex; IL, interleukin; DC, dendritic cells, CCR, CC chemokine receptor; Ag, antigen; CD40L, CD40 ligand; TCR, T cell receptor; dsRNA, double-stranded RNA; LPS, lipopolysaccharide; IFN, interferon; TNF, tumor necrosis factor; Hsp, heat-shock protein; Th1, T helper cell type 1; NK, natural killer.
classical model, attention is given to the identification of TAA and design of TAA-based vaccines. In contrast, the danger model would suggest development of new approaches such as the involvement of professional APC such as DC, redirection of T cells towards the tumor site and evoking inflammatory processes in tumor foci. Also, according to this model, the innate immune system should not be ignored since both the cellular (NK cells, macrophages and neutrophils) and the humoral part (chemokines, cytokines) of the innate immune system could provide the necessary signals to establish the immune response in the context of danger, as opposed to the tolerogenic immune response observed in tumor-bearing hosts. 120 Importantly, vaccination should be repeated until the tumor is completely eliminated in order to avoid default induction of tolerance.
Aside from this theoretical framework, one will also have to pay a great deal of attention to the choice of TAA (and accompanying adjuvant) used for vaccination. Since the tolerance threshold can vary depending on the nature of the TAA, not all TAA are suitable targets for breakdown of immune tolerance. This obstacle derives from the fact that TAA are not by definition tumor rejection antigens (TRA), ie antigens causing tumor rejection (for reviews on TAA and TRA, see Gilboa 30 and Boon et al 121 ) . Whether effective TAA are unique patientspecific antigens or correspond to normal gene products shared among many patients is of important practical value for the design of 'off-the-shelf' tumor vaccines. Therefore, identification of clinically relevant TAA will be a critical area of tumor vaccine research. 30 In this view, ex vivo loading of human DC with clinically relevant TAA in the context of danger (eg necrosis, heat-shock proteins) can hold promise for immunotherapy of cancer. In principle, this approach combines the immune-enhancing properties of DC, induced by danger signals, with the initiation of a cellular anti-tumor immune response induced by TAA and mediated by tumor-specific CTL. This could eventually lead to the eradication of tumor cells in a systemic and specific manner.
Dendritic cells: pivotal players in anti-tumor immune responses
Dendritic cells (DC) form a complex network of antigen-capturing and -presenting cells (APC) defined by morphological, phenotypical and functional criteria which distinguish them from monocytes and macrophages (reviewed by Hart 122 and Banchereau and Steinman 123 ). In this section, we will focus on myeloid DC, which are used in vitro and in vivo to enhance specific immune responses, rather than on lymphoid DC that mediate negative selection in the thymus, resulting in central tolerance. Three major myeloid DC populations have been identified in vivo: (1) epidermal Langerhans' cells (LC); (2) interstitial (or dermal) immature DC; and (3) mature interdigitating DC, found in secondary lymphoid organs. In the early stages of DC research, the limited accessibility of these cells in vivo as well as their difficult ex vivo culture hampered attempts to study this particular cell type in more detail. In the 1990s, this problem was solved by the efforts of various research teams which revealed the hematopoietic lineages through which DC differentiate, and established in vitro expansion protocols to obtain sufficient quantities of DC for clinical use. [124] [125] [126] The unique ability of DC to stimulate primary immune responses stems from several factors. The immature DC type uses elegant systems, including macropinocytosis, mannose receptor-mediated uptake, Fc␥ receptor III (Fc␥RIII)-mediated uptake and phagocytosis to efficiently take up exogenous antigens, either self or non-self, from the periphery. 127 After antigen capture, DC leave the peripheral tissue and migrate via Review VFI Van Tendeloo et al 551 blood or lymphatic vessels to the draining lymph nodes where they activate T cells. In the presence of 'danger' signals, eg viral infection 128 or necrosis, 129 DC will undergo maturation characterized by loss of surface markers associated with antigen-capturing capacity and by upregulation or novel expression of molecules critical for T cell activation, including MHC, CD80 (B7.1), CD86 (B7.2), CD83, CD40, and various adhesion molecules (Figure 2) . 119 Interestingly, mature DC express 10-to 100-fold higher levels of MHC molecules than macrophages, providing more peptide/MHC ligand interactions for T cell receptor involvement and requiring only a few DC to provoke a strong T cell response. 130 Consequently, mature DC are solely capable of activating naive antigen-specific CD4
+ helper T cells. DC-CD4 + T cell interaction conditions the dendritic cell, mainly via CD40 ligand (CD40L) binding, following which the dendritic cell becomes empowered (or 'licensed') to stimulate naive CD8 + CTL precursors (Figure 2) . 131 Other DC-specific genes, such as T cell-attracting chemokines, 132, 133 add to the list of features that give DC their unique potency in initiating T cell responses. It is now clear that mature DC prime T cells to a wide range of foreign proteins, ranging from superantigens 134 that bind directly to MHC molecules to the larger world of standard antigens that require processing prior to presentation, including those from infectious agents 135, 136 and from tumors. 137, 138 This antigen-capturing process was demonstrated to be MHC-independent, creating the possibility of immunizing hosts against antigens derived from MHC-mismatched cells, a process known as cross-priming). The communication between DC and T cells seems to be a dialogue, rather than a monologue, in which DC repond to T cells as well. Activated and memory T cells express ligands from the TNF family including CD40L and TNF-related activation-induced cytokine (TRANCE), 139, 140 which, upon binding to DC via CD40 and receptor activator of NF-B (RANK), respectively, lead to increased DC survival. In the case of CD40 ligation, this interaction will also result in the upregulation of CD80 and CD86, secretion of IL-12 ( Figure 2) , 141, 142 and release of chemokines 143 such as IL-8, macrophage inflammatory protein (MIP)-1␣ and MIP-1␤. IL-12, in particular, is a pivotal cytokine in the induction of a cellular immune response as it can act as a major Th1 differentiation factor, promoting production of IFN-␥ and IL-2 by Th1 cells and, hence, resulting in adequate T cell help for generation of tumor-specific CTL. Furthermore, it activates NK cells, thereby providing a link with the innate immune system (Figure 2 ). 120 Given their central role in controlling immunity and their link with the innate immune system, DC are often called nature's adjuvant. Therefore, DC are logical targets for immunotherapy of cancer. The fact that tumors do not elicit a therapeutic T cell response may be due to the absence of competent DC at the tumor site. Indeed, DC that infiltrate colon and basal-cell skin carcinoma appear to lack expression of CD80 and CD86 costimulatory molecules, 102, 144 which might account for the reduced T cell activity. In addition, tumors may secrete immunosuppressive factors, eg VEGF or IL-10, that impair both DC development (through VEGF) and functional DC maturation (through VEGF and IL-10) ( Figure  1) . 106, 145 In vitro DC generation and modulation of DC functions are now the subject of active research, in order to try and overcome tumor-induced immunodeficiency. As various methods of DC generation for clinical purposes have already been outlined, [146] [147] [148] the next challenge will be to target immunizing Leukemia antigens to DC, either directly or indirectly, in order to allow optimal TAA presentation to the immune system ( Figure 2 ). The ultimate goal will be to prime tumor-specific CTL in vivo and promote tumor eradication. Possible strategies to target TAA to the MHC class I pathway could be fulfilled through pulsing of peptides, either synthetic or unfractionated tumor peptides, 138, 149 tumor lysates, 150 purified TAA, 151 apoptotic cells 152 or through transfer of relevant genes encoding TAA (for reviews on antigen loading of DC, see . Recently, fusions of tumor cells and DC were shown to generate DC-tumor hybrids that efficiently induced primary TAAspecific CTL in vitro and in vivo. [157] [158] [159] Furthermore, differentiation of primary acute leukemia and chronic myeloid leukemia cells towards functional DC has been achieved in vitro and could serve as an attractive strategy for generation of leukemia-specific CTL, bypassing the antigen loading methods described above. 160, 161 Below, we will focus on the use of TAA gene-modified DC for tumor vaccine development.
Design of dendritic cell-based gene therapy of cancer
To date, DC-based vaccines have been translated from the bench to the clinic. The results from phase I clinical trials provide proof of principle that DC presenting TAA can elicit antitumor immune responses in patients, leading to partial or complete regression of tumors. [162] [163] [164] Although these early results are very encouraging, they also suggest the need for modified DC-based vaccines in order to improve the ability to prime TAA-specific T cells and promote anti-tumor immune responses in vivo. In view of this, gene-modified DC might pave the way towards improved tumor vaccines. The major advantage over peptide-pulsed DC vaccines is that genemodified DC could tailor multiple immunodominant epitopes to MHC class I molecules without prior knowledge or need to synthesize MHC class I-restricted antigenic peptides and, more importantly, independently of the HLA type of the patient. When using proteins or lysates as a source of TAA, one major concern is to obtain large numbers of tumor tissue for isolation of sufficient amounts of antigens or lysates, especially when multiple boostings are scheduled. The use of genes, in the form of DNA or mRNA, encoding TAA could overcome this major practical limitation. 155 To date, many in vitro studies have documented TAA gene delivery for induction of primary TAA-specific CTL, generally through viral transduction of human dendritic cells (recently reviewed by Kirk and Mule. 165 The feasibility of expressing TAA in human DC using gene transfer was first reported by Alijagic and co-workers 166 using lipofection. However, gene transfer efficiency was not determined but was reported to be very low. The observed low level of transgene expression could be explained by the nondividing nature of monocytederived DC, rendering them hard to transfect by nonviral means or retroviral vectors. 167 Several groups attempted to bypass this problem by retroviral transduction of rapidly proliferating CD34
+ hematopoietic progenitors and then allowing subsequent differentiation along the DC lineage. [168] [169] [170] Currently, however, most groups working in the field prefer to use monocyte-derived DC (Mo-DC) as this DC source represents an easy-to-access source for tumor vaccine development and Mo-DC can be transduced to high levels using adenovirus [171] [172] [173] or poxvirus 174 vectors. Preclinical murine tumor models have demonstrated that TAA gene-modified DC were effective in inducing therapeutic anti-tumor immunity in vivo. 175, 176 In general, these models were based on artificial TAA, eg ovalbumine (OVA) or ␤-galactosidase (␤-gal), that render the parental tumor more immunogenic. 175, 177 Therefore, conclusions regarding the efficacy of these tumor vaccines should be drawn with extreme caution due to the artificial nature of the tumor itself. Recently, murine DC genetically engineered to express naturally occurring TAA were shown to be capable of priming tumor-specific CTL in vivo. 178, 179 Although the safety issues of viral vectors have been extensively addressed, their use for DC-based vaccines in the human setting raises some concerns. First, recombinant viruses may impair, reduce or suppress antigen presentation capacity of transduced DC. 180, 181 Second, in the case of adenoviral vectors, anti-adenovirus immunity may hamper repeated immunizations due to induction of adenovirus-specific CTL. 182, 183 Therefore, nonviral gene delivery systems for DC-based vaccines could provide a more attractive approach with clinical perspectives. 184 Lipoplex technology as well as gene gun-mediated gene delivery have been tested to transfect cultured human DC. 166, 185 However, the major disadvantage with nonviral vectors is inefficient gene transfer and expression. 173 Notwithstanding, Gilboa and co-workers demonstrated that murine DC pulsed with tumor-derived mRNA were potent antigen-presenting cells in vitro and in vivo. 186 Recently, the same group showed that human DC could also be transfected with mRNA and that mRNA-transfected DC were capable of inducing primary antigen-specific CTL. 187 This RNA approach has the major advantage that it charges DC with the full antigenic spectrum of tumor cells without prior identification of candidate TAA, thereby bypassing the problems related to the cDNA approach, including the limited number of characterized TAA, selection after vaccination of antigen-loss tumor variants and improper choice of TAA. 188 Also, due to the intrinsic instability of mRNA and its lack of integration into the host genome, RNA-based transfection of DC can be a significant advantage over DNA approaches in terms of safety, especially when viral tumor antigens with transforming capacity such as E6 and E7 proteins of the human papillomavirus are considered. 189 Furthermore, when only a small number of tumor cells are available, the technology exists to readily amplify tumor-derived mRNA in vitro. 155 In addition, subtractive hybridization could allow for the enrichment of tumor-specific mRNA, thereby minimizing autoimmune events against self proteins.
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All these data are encouraging and indicate that gene-modified DC have the potential to serve applications in vivo in a wide variety of human cancers, even without prior identification of TAA. It is premature at this stage to conclude that gene-modified DC represent a significant improvement to peptide-pulsed DC as only a limited number of controlled studies have been performed with respect to this issue. In a murine tumor model using ovalbumine or ␤-galactosidase as model TAA, two studies suggested that gene-modified DC were at least equivalent to their peptide-pulsed counterparts in terms of tumor protection in vivo 175, 176 and somewhat superior in terms of CTL induction in vitro. 175 Also, from reports describing the direct comparison of gene-modified to peptide-pulsed human DC, data support the hypothesis that the former exceeded peptide-pulsed DC in CTL generation in vitro, 174 and, importantly, CTL generated by gene-modified DC were able to recognize both known and unknown tumorassociated antigen epitopes. 190 In one recent study, however, comparison with protein-pulsed DC revealed that idiotype protein-pulsed DC induced antigen-specific CTL far more efficiently, as compared to idiotype gene-modified DC. 191 More studies regarding this matter are warranted in order to establish the potential of gene-modified DC.
Future goals in this field comprise determining the optimal route of DC administration as well as the optimal stage of DC maturation for use in tumor vaccines. In addition, DC loaded with the full antigenic spectrum of tumor cells using tumor lysate or total mRNA pulsing should be compared with DC modified with a single TAA gene, in order to assess the level of tumor immunity induced by DC loaded with multiple TAA. Furthermore, since gene-based loading of DC capitalizes on introduction of the antigen in the MHC class I pathway, the question as to whether CD4 + T cell activation using MHC class II presentation is a prerequisite for induction of CTL immunity in vivo, should be carefully addressed in human clinical trials. Indeed, in murine models, the central role of CD4 + T cells in the induction of protective and therapeutic antitumor immunity was established. 177, 192, 193 Recently, Baxevanis et al 194 demonstrated for the first time in patients with metastatic cancer the essential role of CD4 + Th cell-activated DC for optimal CTL-mediated killing in vitro and provide the basis for the design of novel protocols capable of inducing T cell help in vivo.
Concluding remarks
The molecular characterization of human tumor antigens and the increased understanding of the immunological pathways involved in tumor immunity have paved the way for the design of gene-based cellular cancer vaccines. To this end, three cellular sources can be envisaged for genetic modification: tumor cells, effector T cells and dendritic cells. However, before ex vivo immuno-gene therapy can become a realistic treatment modality for cancer, several barriers have yet to be overcome. First, improved (viral) vectors should lead to higher transduction rates and transgene expression. Therefore, carefully designed clinical studies are necessary to assess transduction efficiency, safety and toxicity, and eventually to establish the clinical efficacy of the tumor vaccine. With regard to gene-modified tumor cells, another major issue still unsolved at the clinical level is to determine which is the best cytokine to be released by the tumor cells in order to recruit the immune system. Second, It will be imperative to break down the immunological tolerance against the tumor through reversal of T cell ignorance, anergy or tumor-induced immunosuppression in order to achieve a therapeutic outcome. Use of dendritic cells, whether gene-modified or not, in the context of danger signals could provide a means to initiate a cellular immune response against the tumor.
An additional general feature to be considered when designing immuno-gene therapy of cancer is the complex redundancy of the immune system. Its effectiveness in protecting the body from harmful infections demands a sophisticated network to control the pathways of activation and termination of an immune response, as well as maintenance of life-long tolerance. This suggests that a combination of multiple strategies, gene-based or not, acting at different levels may be advantageous to boost the immune system against the tumor. Moreover, it is believed that the breakdown of tolerance to tumors will require, in addition to the strategies discussed in this review, complementary strategies that specifically counteract the active tumor-induced immunosuppression. Furthermore, means for amplification of vaccine potency (eg by CTLA-4 blockade) in order to enhance the therapeutic outcome should not be overlooked. 195, 196 Review VFI Van Tendeloo et al
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As vector technology as well as methods to monitor tumorspecific CTL responses in cancer patients will continue to improve, it is anticipated that the promising preliminary results of gene-modified tumor vaccines will soon find their place to treat cancer in the clinical setting.
